Haemonetics Corporation financials
Key figures from Haemonetics Corporation's filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $339M | $321M | +5.6% |
| Net income | $33M | $34M | -3.0% |
| Free cash flow | $44M | $14M | +225.6% |
| Gross margin | 59.8% | 59.8% | -0.1 pts |
| Operating margin | 16.9% | 16.8% | +0.2 pts |
| Net margin | 9.7% | 10.6% | -0.9 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Mar 2026 | $1.3B | $97,308 | 0.0% | $260M | $2.05 |
| FY Mar 2025 | $1.4B | $167,679 | 0.0% | $142M | $3.31 |
| FY Mar 2024 | $1.3B | $118M | 9.0% | $144M | $2.29 |
| FY Apr 2023 | $1.2B | $115M | 9.9% | $82M | $2.24 |
| FY Apr 2022 | $993M | $43M | 4.4% | $76M | $0.84 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.